South Africa Approves Lenacapavir for HIV Prevention
South Africa's Health Product Regulatory Authority (SAHPRA) has approved lenacapavir, a twice-yearly HIV prevention drug.
The drug is recommended for adults and adolescents weighing at least 35 kg, who are HIV negative and at risk of getting HIV.
Lenacapavir for PrEP should always be used in combination with safer sex practices, such as using condoms, to reduce the risk of getting other sexually transmitted infections.
SAHPRA's approval paves the way for the country to roll out the drug, expected to be available by April 2026, with South Africa being among the first countries to receive doses through a donation facilitated by the Global Fund and PEPFAR.
With approximately two million people on the daily HIV prevention pill since 2016, South Africa has the largest pre-exposure prophylaxis (PrEP) programme globally.
Author's summary: SAHPRA approves lenacapavir for HIV prevention in South Africa.
More News
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- Canada's youth facing growing opioid crisis: Calls for urgent action
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Deadline is Dec. 31 to apply for Renew NC grants - Hendersonville Lightning
- iOS 26.1 Coming Soon: New Features for Your iPhone and Release Date
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Bank of Canada expected to cut interest rate this week as forecasters see more weakness to come for economy
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups